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Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder that affects multiple organ systems
throughout the body. Dysregulation of the mammalian target of rapamycin (mTOR) pathway is implicated in the
disease pathology, and evidence exists to support the use of mTOR inhibitors in treatment. The mTOR pathway has
also been investigated as a potential treatment target for several other rare diseases. TSC research has highlighted
the value of pursuing targeted therapies based on underlying molecular pathophysiology. One goal of current
research is to identify the role of mTOR inhibition in neurologic and developmental disorders apart from TSC. There
is also particular interest in the potential role of mTOR inhibitors in preventing seizures, neurodevelopmental
disabilities, renal tumors, cutaneous tumors, and other manifestations typically seen in TSC. It is foreseeable that use
of mTOR inhibition to prevent long-term morbidity in TSC will become mainstream therapeutic practice. This
review will provide an overview of the relationship between the mTOR pathway and TSC disease pathology,
summarize the clinical evidence supporting the use of mTOR inhibitors for treatment of the various manifestations
of TSC, and discuss the potential therapeutic role of mTOR inhibitors in several rare diseases.
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Tuberous sclerosis complex (TSC) is an autosomal dom-
inant genetic disorder that typically results in the growth
of hamartomas in multiple major organ systems [1–3].
TSC is a rare disease that is estimated to occur in one in
6000 births, affecting approximately 1.5 million people
worldwide [1, 2, 4]. Although TSC can manifest in many
organs to different degrees of severity, it is primarily
characterized by neurologic manifestations (including
seizures); neurodevelopmental disabilities (e.g., intellec-
tual disability and autism); and lesions in the brain,
lungs, kidneys, and skin [1]. Updated TSC consensus
recommendations established in 2012 now recommend* Correspondence: David.Franz@cchmc.org
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rapamycin (mTOR) inhibitors in certain cases, which
provides an opportunity to treat multiple manifestations
of TSC simultaneously [5]. This review evaluates the
current role of and available clinical data on mTOR in-
hibitor use in TSC and discusses potential future roles
for mTOR inhibitors in TSC and similar diseases that
are currently under investigation.Materials and methods
We conducted a search of the published literature on
PubMed/Medline for, and participated in, key clinical
studies of mTOR inhibitors in treating subependymal
giant cell astrocytomas (SEGAs), angiomyolipomas,
lymphangioleiomyomatosis (LAM), angiofibromas, and
epilepsy in patients with TSC. For other rare diseases,
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syndrome”, “Down syndrome”, and “Neurofibromatosis”.
Manifestations associated with TSC
Cortical tubers, subependymal nodules (SENs), and
SEGAs are the primary abnormalities found in the brain
[1]. Cortical tubers, which are formed during embryo-
genesis, can be present at birth and have been observed
in 80% to 90% of patients with TSC [1, 2, 6]. Tubers are
thought to be associated with the development of sei-
zures, intellectual disability, behavioral difficulties, and
autism [6, 7]. SENs, which are asymptomatic hamarto-
mas that protrude into the ventricles of the brain, occur
in approximately 90% of individuals, and in about 5% to
20% of individuals they can develop into SEGAs [1, 8].
SEGAs are slow-growing glioneuronal tumors that de-
velop near the foramen of Monro and have the potential
to cause hydrocephalus, increased intracranial pressure,
and death secondary to impeded ventricular cerebro-
spinal fluid flow [1, 6]. Prior to the use of pharmacologic
therapy to reduce tumor volume, treatment for growing,
symptomatic SEGAs has been mainly surgical resection
[9, 10].
In the central nervous system, epilepsy is the most com-
mon medical disorder in patients with TSC, affecting up
to 96% of individuals [11, 12]. Focal seizures and infantile
spasms are the most common seizure types in patients
with TSC. Infantile spasms are common during infancy
(i.e., first year of life), occurring in up to one-third of chil-
dren with TSC [10, 11]. Early onset of infantile spasms is
associated with poor developmental outcomes and worse
future seizure control [1, 13, 14].
TSC involves multiple organ systems, including the
brain, kidneys, lungs, heart, and skin. Renal manifesta-
tions occur in approximately 55% to 90% of patients
with TSC, with angiomyolipomas occurring in up to 75%
of patients [6]. Renal angiomyolipomas are the most
common cause of mortality in patients with TSC be-
cause of potential renal failure or hemorrhage [15].
LAM is the most common lung manifestation in TSC,
characterized by development of cystic lesions in the
lung. LAM can occur in patients with TSC but can also
occur sporadically in non-TSC individuals [16]. LAM oc-
curs in approximately 30% to 40% of patients with TSC,
is seen almost exclusively in women, and can lead to de-
struction of lung parenchyma, resulting in progressive
dyspnea on exertion and recurrent pneumothorax [16–
18]. Cardiac rhabdomyomas are a common initial mani-
festation of TSC and occur in 33% of patients. Rhabdo-
myomas are typically asymptomatic and spontaneously
regress with age [19, 20]; however, in rare instances, the
location of the tumor can cause arrhythmia and heart fail-
ure [21]. Most patients (> 90%) exhibit skin manifesta-
tions, including hypomelanotic macules (ash leaf spots),angiofibromas and/or cephalic plaques, ungual or periun-
gual fibromas, shagreen patches, and confetti skin lesions.
Angiofibromas are present in approximately 80% of indi-
viduals with TSC older than the age of 5 years, and typic-
ally develop on the face [3]. The characteristic red or pink
nodules often develop within the first few years of life and
become more pronounced with age [22]. Although mul-
tiple dermatologic treatments exist (including surgical ex-
cision in some cases), fibroma often recurs [22].mTOR pathway in the pathogenesis of TSC
In normal cells, the mTOR signaling cascade (also
known as the phosphatidylinositol 3-kinase [PI3K]/pro-
tein kinase B [Akt]/mTOR pathway) plays an important
role in cell growth, proliferation, and survival (Fig. 1)
[23]. Stimulants, such as growth factors (e.g., insulin-like
growth factor-1 [IGF-1]), bind to tyrosine kinase recep-
tors (e.g., IGF-1R), which leads to the phosphorylation of
PI3K [23]. This activation of PI3K results in a cascade of
phosphorylation events, resulting in the activation of
Akt, which in turn inhibits the TSC1/TSC2 complex,
which negatively regulates mTOR by acting as a
GTPase-activating protein toward Ras homolog enriched
in brain (Rheb), a direct and positive regulator of
mTOR. As a result, inhibition of the TSC1/TSC2 com-
plex results in the overactivation of mTOR, leading to
cell growth and proliferation [23–25]. Two additional
proteins, the NF1-encoded neurofibromin and the NF2-
encoded Merlin, also act as negative regulators of the
mTOR pathway [26, 27]. mTOR forms two distinct mul-
tiprotein complexes, mTORC1 and mTORC2, which are
differentiated by their interaction partners (regulatory as-
sociated protein of mTOR [RAPTOR] for mTORC1 and
rapamycin-insensitive companion of mTOR [RICTOR]/
SIN1 for mTORC2), substrate selectivity, and sensitivity
to rapamycin (sirolimus) and its analogs (e.g., everolimus)
[25, 28]. The downstream effects of mTORC1 include
gene transcription and protein translation, cell prolifera-
tion and survival, and angiogenesis, while mTORC2 is
thought to mediate cytoskeletal dynamics [28]. Dysregula-
tion of the mTOR pathway has been implicated in the de-
velopment of many cancers, including TSC, along with
other neurologic disorders [23, 28].
TSC is caused by a mutation in either the TSC1 or the
TSC2 gene, the loss of which triggers constitutive activa-
tion of the mTOR signaling pathway, leading to abnormal
cell growth/proliferation and the subsequent formation of
hamartomatous lesions [25, 29]. The discovery of the rela-
tionship between TSC1/TSC2 and mTOR has resulted in
important clinical advances in the use of mTOR inhibi-
tors, particularly sirolimus and its analog everolimus, for
the treatment of several TSC manifestations. Sirolimus
and everolimus both work by binding to and forming a
Fig. 1 The mammalian target of rapamycin (mTOR) signaling pathway and possible involvement of rare diseases in the pathway. Stimulants such
as insulin-like growth factor bind to tyrosine kinase receptors, which leads to the phosphorylation of phosphatidylinositol 3-kinase (PI3K) [23]. A
cascade of subsequent phosphorylation events results in the activation of protein kinase B (AKT), which in turn phosphorylates and inhibits the
TSC1/TSC2 complex, a negative regulator of mTOR that is directed against the positive regulator Ras homolog enriched in brain (Rheb). As a
result, inhibition of the TSC1/TSC2 complex results in the activation of mTOR [23–25]. NF1-encoded neurofibromin and NF2-encoded Merlin
proteins also act as negative regulators of the mTOR pathway. Neurofibromin functions as a Ras-GTPase activating protein that inhibits the actions
of Ras on PI3K [26], while Merlin acts directly on mTOR complex 1 (mTORC1) [27]. Sirolimus and everolimus both bind to and form complexes
with FK506-binding protein-12 (FKBP12), resulting in the inhibition of mTORC1 activity [24]. While mechanisms are complex and not fully clear in
Leigh and Down syndrome, evidence has shown a relationship between mTOR activity and ATP (Leigh syndrome), and decreased autophagy with
increased protein production and oxidation with mTOR hyperactivation (Down syndrome) [62, 65, 66]
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then inhibits mTORC1 (Fig. 1) [24].
mTOR inhibitors for the management of TSC-
associated manifestations
TSC-associated SEGA
Experience with sirolimus in treating SEGA was evalu-
ated in case reports and as a secondary end point in a
phase two trial with a small number of patients. In these
cases, sirolimus demonstrated an observable regression
of SEGA lesions [30–32].
Everolimus has been studied more extensively in treating
SEGA through long-term phase 2 and 3 studies [33–36]. In
a 6-month open-label phase 2 study consisting of 28 pa-
tients, everolimus demonstrated a significant reduction in
tumor volume compared with baseline, with approximately
75% of patients experiencing a ≥ 30% reduction in SEGA
volume and 32% experiencing a ≥ 50% reduction [33]; these
reductions were sustained during the extension phase of
the trial (median 5.65 years of treatment) [37]. In a ran-
domized, double-blind, placebo-controlled, phase 3 studyof 117 patients with SEGA associated with TSC, treatment
with everolimus (median 9.6 months) was associated with a
significantly higher SEGA response (≥ 50% reduction of
SEGA volume) rate compared with placebo (35% vs. 0%;
p < .0001) [35]. An analysis of 111 patients who received
at least one dose of everolimus (in either the double-blind
or a subsequent open-label phase) revealed that SEGA re-
sponse increased to 57.7% over a median duration of
47.1 months (3.9 years), and the median reduction in SEGA
volume was maintained, and even slightly increased, over
the duration of the study [38]. Taken together, phase 2 and
3 clinical data on everolimus supported its use in the
setting of TSC-associated SEGA, with the phase 2 results
leading to the US Food and Drug Administration (FDA)
approval of everolimus for the treatment of SEGA in
pediatric and adult patients with TSC [39].
TSC-associated renal angiomyolipoma
Everolimus was evaluated for the management of renal
angiomyolipoma in the large phase 3 EXIST-2 trial and
in a subset of the patients from the EXIST-1 trial who
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EXIST-2, the angiomyolipoma response rate (≥ 50%
reduction in volume in absence of other factors) after
approximately 8 months of treatment was 42% for pa-
tients taking everolimus compared with 0% in patients
receiving placebo (p < .0001) [40], which increased to
54% in patients treated with everolimus for a median of
29 months [42], and 58% at the completion of the open-
label extension phase (median exposure, 46.9 months)
[43]. Based on the results from the core phase of EXIST-
2, everolimus was approved by the FDA for the treat-
ment of adult patients with renal angiomyolipoma and
TSC [39]. Similar to the findings of EXIST-2, a subset of
patients with SEGA and angiomyolipoma in EXIST-1
(largely pediatric population) reported angiomyolipoma
response rates of 53.3% for everolimus and 0% for placebo
after a median of 9.6 and 8.3 months of treatment, re-
spectively; 80% of patients achieved a ≥ 50% reduction in
renal angiomyolipoma volume after 48 weeks (11 months)
of treatment [41].
Sirolimus has not been approved for the management of
renal angiomyolipoma, but has been evaluated in several
small open-label phase 2 clinical studies [32, 44–46].
Bissler et al. found that sirolimus reduced the size of
angiomyolipoma lesions and improved lung function over
12 months of treatment [44]. However, 12 months after
sirolimus was discontinued, lesion size and several lung
function parameters approached baseline levels, suggest-
ing that therapy with mTOR inhibition might necessitate
long-term or indefinite use [44]. Davies et al. conducted a
longer study and found that 50% of patients reported a
positive angiomyolipoma response (disappearance of le-
sions or ≥ 30% reduction in sum of longest diameter of
target lesions) over a 2-year period [45]. One phase 2,
multicenter trial of sirolimus in adults with TSC evaluated
the effects of sirolimus on multiple lesion types. Over a
period of 1 year of treatment, they observed reductions in
renal angiomyolipoma size, SEGA size, and liver angio-
myolipoma size, with subjective improvement in skin le-
sions and reduction of vascular endothelial growth factor
(VEGF) D [32].
TSC-associated LAM
Sirolimus and everolimus have both been evaluated for
the management of LAM in a number of studies consist-
ing primarily of patients with sporadic LAM, although
small numbers of patients with TSC-associated LAM
were also included [47–50]. In the multicenter placebo-
controlled MILES study, 89 patients with LAM (8 with a
codiagnosis of TSC) receiving treatment with sirolimus
(n = 46) over 12 months exhibited improvements in
forced vital capacity (FVC) and quality of life, as well as
stabilization of forced expiratory volume in 1 second
(FEV1) [47]. These findings led to the FDA approval ofsirolimus for the treatment of LAM [51]. Two retro-
spective studies also evaluated sirolimus in treating
LAM [48, 49], reporting improved or stabilized lung
function even at serum trough levels < 5 ng/mL [48],
along with sustained effects over a treatment period of
approximately 3.5 years [49].
Recently, everolimus was evaluated in a prospective
study that included 24 patients (5 with TSC-LAM) and
showed improvements in FEV1, stabilization of FVC,
and reductions in VEGF-D and collagen IV; however,
optimal dosing of everolimus for this indication needs
further investigation [50]. As a result, everolimus has yet
to receive approval for use in the LAM setting.
TSC-associated seizures
Although no mTOR inhibitors are currently indicated
specifically for the treatment of seizures associated with
TSC, recent clinical evidence has shown promise for this
use in this setting. The results of several small reports
suggest that sirolimus may be effective for the treatment
of TSC-associated seizures [52–54]. Sirolimus therapy
given over 10 months in a 10-year-old girl reduced daily
seizure activity from 5–10 times/day to 1–5 times/day
and resulted in the cessation of seizure clusters [52]. A
case series of seven children with TSC found that all pa-
tients experienced seizure control after 12 months of
treatment with sirolimus [53]. A second case series of
seven children with TSC and refractory seizures reported
that most patients had 50% to 90% reductions in num-
bers of seizures [54]. In a recent, small, randomized trial
of 23 children (ages 3 months to 12 years) with TSC,
treatment with sirolimus decreased overall seizure fre-
quency 41% over standard of care, but this change failed
to reach statistical significance (p = .11) [55].
Use of everolimus in TSC-associated refractory sei-
zures has also been evaluated [33, 56]. A prospective,
phase 1/2 trial directly evaluating everolimus in man-
aging refractory seizures associated with TSC showed a
reduction in seizure frequency of ≥ 50% in 12 of 20 pa-
tients after 12 weeks of treatment [56]. In a phase 2
study, everolimus therapy was associated with a clinically
relevant reduction in the overall frequency of clinical
and subclinical seizures (median change, −1 seizure;
p = .02) in patients with SEGA. Of the 16 patients for
whom electroencephalographic data were available, seizure
frequency decreased in nine patients after 6 months; five
additional patients did not experience an event [33]. Results
from the first phase 3 study to evaluate an mTOR inhibitor
(everolimus) for refractory seizures associated with TSC
were recently reported (ClinicalTrials.gov NCT01713946)
[57]. This prospective, randomized, double-blind, multicen-
ter study compared everolimus at two different trough
levels (low exposure, 3–7 ng/mL; high exposure, 9–15 ng/
mL) with placebo in reducing seizures (N = 366) when
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18 weeks of treatment, the median percentage reduction in
seizure frequency was significantly higher with everolimus
(29.3% for everolimus low exposure and 39.6% for everoli-
mus high exposure compared with 14.9% with placebo
[p = .0028 and p < .0001, respectively]), and the propor-
tion of responders (≥ 50% reduction in seizure frequency)
was significantly greater with everolimus (28.2% for
everolimus low exposure and 40% for everolimus high
exposure compared with 15.1% with placebo [p = .0077
and p < .0001, respectively]) [57]. These preliminary find-
ings indicate that adjunctive treatment with everolimus
may be an effective option in reducing refractory seizures
in patients with TSC.
TSC-associated neuropsychiatric disorders (TAND)
mTOR inhibitors may also be a rational candidate for the
management of neurodevelopmental/neuropsychiatric dis-
abilities associated with TSC, including intellectual disabil-
ity and autism. Indeed, a recent preclinical study of adult
rats with TSC2 mutations and developmental status epi-
lepticus, and a case study of a patient with TSC both re-
ported improvements in social deficit behaviors, including
autism-related behaviors, following mTOR inhibitor ther-
apy with everolimus [58, 59]. However, mTOR inhibitors
have not been adequately evaluated or approved for the
treatment of neurodevelopmental disabilities in TSC, es-
pecially in young infants. It is also essential that we estab-
lish the safety and overall impact of mTOR inhibitors in
the pediatric population before larger, definitive clinical
trials can be pursued. In the future, we await further infor-
mation on effects of mTOR inhibitors on TSC-associated
neuropsychiatric disorders, including secondary analyses
from EXIST-3, and results from several phase 2 trials
(NCT01289912, NCT01954693).
Rationale for potential use of mTOR inhibitors in
other novel indications
In addition to TSC, mTOR inhibition is being explored
in other rare diseases for which mTOR dysregulation
has been noted.
Leigh syndrome
In Leigh syndrome, genetic defects result in disruption
of mitochondrial function, which contributes to numer-
ous health problems. Patients can have symptoms such
as respiratory abnormalities, ocular and other cranial
nerve palsies, involuntary movements, motor delays, in-
tellectual disabilities, and seizures [60]. Although the
time of onset can vary, it typically occurs in the first year
of life. Leigh syndrome is characterized by diffuse multi-
focal spongiform degeneration in various parts of the
brain, and many patients die within a few years after
symptom onset [60].In a preclinical study with Ndufs4 knockout mice (the
protein product of the Ndufs4 gene is involved in the as-
sembly, stability, and activity of complex I of the mitochon-
drial electron transport chain), rapamycin administration
increased survivability and health [61]. The mechanism be-
hind this is not entirely understood; however, it is believed
that reduction of mTOR activity may shift cell metabolism
toward amino acid catabolism and away from glycolysis
and, thus, reduce the buildup of glycolytic intermediates
that are associated with Leigh syndrome [61].
Additional research has suggested mTOR inhibition
may aid in Leigh syndrome through preservation of
adenosine triphosphate (ATP). Mitochondria provide en-
ergy to the cell through ATP, which has been found to
be decreased in mitochondrial disorders; this leads to
the degeneration of neurons, as in Leigh syndrome [62].
In an in vitro study, rapamycin was introduced to neur-
onal cells with mitochondrial defects, resulting in a signifi-
cant rise in ATP level while protein production slowed
[62]. It is theorized that the decrease in the energy-
consuming process of protein synthesis with mTOR inhib-
ition allows for more ATP to be spared [62].
Although investigation into the use of mTOR inhibi-
tors in Leigh syndrome is at a very early stage, preclin-
ical results are promising because there are currently no
effective therapies for this disease.
Down syndrome
Down syndrome is a genetic disorder associated with in-
tellectual disability caused, in most cases, by trisomy of
human chromosome 21 [63]. Down syndrome is charac-
terized by abnormalities in dendritic morphology and syn-
aptic plasticity, and mTOR is believed to be involved in
the growth and branching of dendrites in the hippocam-
pus [64]. The mTOR activity of dendrites in the hippo-
campus has been shown to be increased in a mouse
model of Down syndrome [64]. This increase was subse-
quently reversed after administration of rapamycin. Stud-
ies are underway to investigate whether rapamycin can
reverse learning deficits associated with Down syndrome.
Hyperactivation of the PI3K/Akt/mTOR pathway was
also observed in autopsy samples of patients with Down
syndrome compared with controls [65]. A causative fac-
tor of Down syndrome is hypothesized to be the triplica-
tion of amyloid-beta protein gene, resulting in excess
protein proliferation. In combination with decreased au-
tophagy as a result of increased mTOR activation, this
may result in the accumulation of amyloid beta peptide
in the brain and contribute to the neurodegenerative
process and to eventual Alzheimer’s-like dementia in
these patients [65]. Oxidative stress is also believed to
have a role in neurodegenerative diseases such as Down
syndrome. A mouse model of Down syndrome demon-
strated that protein oxidation was increased possibly due
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sult of mTOR pathway hyperactivation [66]. Signs of
protein oxidation in cells were reduced when rapamycin
was introduced [66].
Neurofibromatosis types 1 and 2
Neurofibromatosis is an autosomal dominant genetic
disorder that is further classified into subtypes 1 and 2.
Neurofibromatosis types 1 and 2 are caused by inactivat-
ing mutations in NF1 and NF2 genes, respectively [67].
The loss of NF1 encodes for the protein neurofibromin
and results in development of neurofibromas on or
around peripheral nerves, along with pigmented tumors
of the skin and iris [67]. Plexiform neurofibroma occur in
up to one-third of individuals with neurofibromatosis type
1 and can cause disfigurement, compression of other
bodily structures, neurologic dysfunction, and pain [68].
Evidence suggests that neurofibromin is involved in nega-
tively regulating the mTOR pathway. A phase 2 study in-
volving patients with progressive plexiform neurofibromas
treated with sirolimus showed a modestly increased time
to progression [68]. However, a similar phase 2 study that
evaluated sirolimus with nonprogressive plexiform neuro-
fibromas showed that sirolimus did not cause any tumor
shrinkage [69]. A case series involving patients with symp-
tomatic plexiform neurofibromas showed that, although
sirolimus did not shrink tumor volume, pain was alleviated
[70]. The lack of an antitumor response with sirolimus in
neurofibromatosis type 1 may be caused by alternative
compensatory mechanisms (e.g., feedback activation of Akt
activity) following mTOR inhibition [71].
Neurofibromatosis type 2, the rarer of the two sub-
types, involves the loss of the NF2 gene, which encodes
for the regulator protein merlin. The loss of merlin leads
to development of benign tumors called schwannomas,
which can grow along auditory nerves, leading to hear-
ing loss, and can compress nerves, leading to increased
intracranial pressure, nerve dysfunction, and pain [67].
Similar to neurofibromin, merlin has been found to be a
negative regulator of the mTOR pathway [72]. Rapamy-
cin arrested schwannoma tumor growth in mice and in
an in vitro model [72]. However, in a phase 2 study
evaluating everolimus in the treatment of progressive
vestibular schwannomas, none of the patients experi-
enced a response (≥ 15% reduction in tumor volume)
[73]. The activation of negative feedback loops following
mTOR inhibition may also explain the limited efficacy of
everolimus in vestibular schwannomas [73].
Safety considerations with mTOR inhibition with
TSC
Current research strongly suggests that mTOR inhib-
ition, particularly with everolimus, seems to remain ef-
fective and safe over extended duration of treatment forcertain TSC manifestations. However, adverse events (AEs)
considered to be class effects of mTOR inhibitors should
be taken into consideration when using sirolimus or evero-
limus, including noninfectious pneumonitis, infections,
oral ulceration (e.g., stomatitis), impaired wound healing,
and metabolic events (e.g., hyperglycemia, dyslipidemia)
[39, 51]. These AEs may be appropriately managed by dose
interruption or adjustment depending on severity of the
event [39]. While long-term data on sirolimus in the TSC
setting are lacking, clinical experience with everolimus in
patients with TSC and renal angiomyolipoma or SEGA in-
dicate that long-term everolimus therapy is generally well
tolerated, with no new safety signals and the majority of
AEs being mild to moderate in severity [36–38, 43, 74, 75].
Long-term mTOR inhibition in TSC
Although mTOR inhibitors are being investigated for
the previously mentioned novel indications simply as a
possible treatment option at this stage, the use of mTOR
inhibitors in TSC has already been established and ne-
cessitates further investigation into the effects of long-
term treatment.
TSC is a lifelong condition that can manifest itself at a
very early age, and it is possible that patients, including
children, will need indefinite treatment with an mTOR
inhibitor. Some of the later manifestations of TSC may be
alleviated or prevented by early treatment with an mTOR
inhibitor; however, initiation of therapy in children and
young adolescents may have other consequences as well.
Therefore, it is important to discuss the efficacy and safety
of mTOR inhibitor treatment in youth and its potential
long-term effects on growth and maturation.
If patients are to undergo mTOR treatment long-term,
sustainability of response is important. The recent long-
term data from EXIST-1 [38] and EXIST-2 [43] showed
a sustained and more pronounced clinical benefit of
everolimus compared with the shorter-term, primary
analyses [35, 40]. Alternatively, in a subset of evaluable
patients from EXIST-2 who were followed after discon-
tinuation of everolimus (n = 7), angiomyolipoma lesion
volume increased by more than 50% between everolimus
discontinuation and 48 weeks after treatment [76].
These findings underscore the necessity of sustained
treatment in TSC.
Although data on long-term exposure of mTOR inhibi-
tors in youth, including effects on patient growth and sex-
ual maturation, are limited, the EXIST-1 study reported
that everolimus had no significant effect on puberty or de-
velopment in patients with TSC after a median exposure
of 47 months [38]. In addition, a retrospective analysis in
a renal transplant population in which mTOR inhibitors
were also used examined a cohort of 31 patients and re-
ported that long-term mTOR therapy had no impact on
growth and pubertal development after a mean follow-up
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1 population may provide additional evidence of the effect
of everolimus on growth and sexual maturation in the
youth population.
Conclusions and future directions
Recent research in TSC has underlined the value of pur-
suing targeted therapies based on underlying molecular
pathophysiology. TSC serves as a model for modification
of acquired and inherited genetic defects causing brain
dysfunction. A goal of current research is to identify the
role of mTOR inhibition in neurologic and developmen-
tal disorders beyond that of TSC (e.g., Leigh syndrome,
Down syndrome, and neurofibromatosis types 1 and 2),
which nonetheless share a common feature of mTOR
pathway hyperactivation. A better understanding of the
molecular pathology of these seemingly diverse inherited
and acquired brain diseases is necessary to achieve this
goal. The recruitment of and performance of patients in
basic science and particularly clinical studies is also a
major challenge. However, available results in these areas
show promise that, after further research, mTOR inhib-
ition may eventually become a therapy option for these
neurologic disorders where few options are currently
available.
In addition to furthering research of mTOR inhibition
in rare neurologic disorders, future research will also
focus on defining the optimal use of mTOR inhibitors in
TSC, including dosages for short- and long-term use, as
well as age at which to initiate therapy. There has been
longstanding interest in identifying treatment strategies
for patients with TSC diagnosed at early ages where the
potential effects of mTOR inhibitors or other therapies
could drastically improve or even prevent the develop-
ment of several TSC manifestations, including seizures,
developmental delay, autism, renal disease, cutaneous
tumors, and other lesions, by initiating treatment with
mTOR inhibitors early in life. mTOR inhibitors are in-
creasingly being used not only for the hamartomatous
and oncologic manifestations of TSC, but also as ad-
junctive therapy for epilepsy and intellectual disability.
Current research is expected to lead to a better defin-
ition of the roles of these therapies and their associated
toxicities. As a result, the use of mTOR inhibition in
TSC, including its use to prevent long-term morbidity,
such as intellectual disability, autism, and refractory
seizures, may be incorporated into clinical practice in
the coming years.
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TSC: Tuberous sclerosis complex; VEGF: Vascular endothelial growth factor
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